AXSM has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
AXSM has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Gross Margin % is calculated as gross profit divided by its revenue. Axsome Therapeutics's Gross Profit for the three months ended in Dec. 2024 was $108.3 Mil. Axsome Therapeutics's Revenue for the three months ended in Dec. 2024 was $118.8 Mil. Therefore, Axsome Therapeutics's Gross Margin % for the quarter that ended in Dec. 2024 was 91.15%.
The historical rank and industry rank for Axsome Therapeutics's Gross Margin % or its related term are showing as below:
During the past 12 years, the highest Gross Margin % of Axsome Therapeutics was 91.37%. The lowest was 89.61%. And the median was 90.37%.
Axsome Therapeutics had a gross margin of 91.15% for the quarter that ended in Dec. 2024 => Durable competitive advantage
The 5-Year average Growth Rate of Gross Margin for Axsome Therapeutics was 0.00% per year.
The historical data trend for Axsome Therapeutics's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Axsome Therapeutics Annual Data | |||||||||||||||||||||
Trend | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | Dec24 | |||||||||||
Gross Margin % | Get a 7-Day Free Trial |
![]() |
![]() |
- | - | 89.61 | 90.37 | 91.37 |
Axsome Therapeutics Quarterly Data | ||||||||||||||||||||
Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | Dec24 | |
Gross Margin % | Get a 7-Day Free Trial |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
89.69 | 91.60 | 90.76 | 91.95 | 91.15 |
For the Biotechnology subindustry, Axsome Therapeutics's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Axsome Therapeutics's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Axsome Therapeutics's Gross Margin % falls into.
Gross Margin is the percentage of Gross Profit out of sales or Revenue.
Axsome Therapeutics's Gross Margin for the fiscal year that ended in Dec. 2024 is calculated as
Gross Margin % (A: Dec. 2024 ) | = | Gross Profit (A: Dec. 2024 ) | / | Revenue (A: Dec. 2024 ) |
= | 352.4 | / | 385.693 | |
= | (Revenue - Cost of Goods Sold) | / | Revenue | |
= | (385.693 - 33.303) | / | 385.693 | |
= | 91.37 % |
Axsome Therapeutics's Gross Margin for the quarter that ended in Dec. 2024 is calculated as
Gross Margin % (Q: Dec. 2024 ) | = | Gross Profit (Q: Dec. 2024 ) | / | Revenue (Q: Dec. 2024 ) |
= | 108.3 | / | 118.766 | |
= | (Revenue - Cost of Goods Sold) | / | Revenue | |
= | (118.766 - 10.514) | / | 118.766 | |
= | 91.15 % |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Axsome Therapeutics (NAS:AXSM) Gross Margin % Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Axsome Therapeutics had a gross margin of 91.15% for the quarter that ended in Dec. 2024 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Thank you for viewing the detailed overview of Axsome Therapeutics's Gross Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.
Nick Pizzie | officer: Chief Financial Officer | 25 BROADWAY, 9TH FLOOR, NEW YORK NY 10004 |
Mark E Saad | director | C/O CYTORI THERAPEUTICS, INC., 3020 CALLAN ROAD, SAN DIEGO CA 92121 |
Mark L. Jacobson | officer: Chief Operating Officer | 200 BROADWAY, 3RD FLOOR, NEW YORK NY 10038 |
Mark Coleman | director | 25 BROADWAY, 9TH FLOOR, NEW YORK NY 10004 |
Roger Jeffs | director | |
Susan Mahony | director | LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285 |
Hunter R. Murdock | officer: General Counsel | 22 CORTLAND STREET, 16TH FLOOR, NEW YORK NY 10007 |
Herriot Tabuteau | director, 10 percent owner, officer: CHIEF EXECUTIVE OFFICER | |
David C Marek | officer: Chief Commercial Officer | C/O WEBMD HEALTH CORP., 111 EIGHTH AVENUE, NEW YORK NY 10011 |
John Golubieski | officer: Chief Financial Officer | C/O LANTHEUS HOLDINGS, INC., 331 TREBLE COVE ROAD, NORTH BILLERICA NY 01862 |
Myrtle S Potter | director | 10 FINDERNE AVE, BRIDGEWATER NJ 08807 |
Randall Kaye | officer: Chief Medical Officer | 11388 SORRENTO VALLEY ROAD, STE. 200, SAN DIEGO CA 92121 |
Ames Constance | officer: Vice President, Finance | 25 BROADWAY, 9TH FLOOR, NEW YORK NY 10004 |
Antecip Capital Llc | 10 percent owner | 630 5TH AVENUE, SUITE 2074, NEW YORK NY 10111 |
From GuruFocus
By Marketwired • 01-31-2025
By Marketwired • 03-05-2025
By GuruFocus News • 02-10-2025
By GuruFocus News • 03-03-2025
By Marketwired • 02-24-2025
By Marketwired • 12-30-2024
By GuruFocus News • 02-14-2025
By GuruFocus News • 01-22-2025
By Marketwired • 01-30-2025
By GuruFocus News • 12-30-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.